Understanding Epilepsies with In Vitro Disease Models

4-AP model SCN1A model Developmental model

Epilepsy, a prevalent neurological disorder, manifests as recurrent unprovoked seizures across various syndromes. Despite advancements in antiepileptic drugs, a significant proportion of patients remain unresponsive to current treatments, highlighting the need for novel therapeutic avenues.

At NeuroProof, we address this challenge with cutting-edge in vitro screening assays designed to probe the mechanisms of epileptogenesis and evaluate the efficacy of emerging antiepileptic compounds. Our assays offer a deeper understanding of the epileptic condition and aid in the development of targeted therapies.

Our Approach:

  • Diverse Assay Models: We have developed specialized in vitro models tailored with our MEA approach and sophisticated data analysis to investigate different aspects of epilepsy, including:
    • 4-AP Model: Mimics epileptiform activity induced by 4-aminopyridine, aiding in the study of seizure mechanisms.
    • SCN1A Model: Focuses on mutations in the SCN1A gene associated with Dravet syndrome, a severe form of epilepsy.
    • Developmental Model: Explores the impact of developmental factors on epileptogenesis, offering insights into early intervention strategies.

  • Human iPSC-Derived Neurons: Our assays leverage human induced pluripotent stem cell (iPSC) technology, enhancing translational relevance and facilitating drug discovery in a human-specific context.
  • Comprehensive Analysis: Utilizing advanced classification algorithms, we assess the excitatory or pro-convulsive potential of test compounds. Our side-effect assays provide valuable insights into compound safety profiles.
  • Probing Pro-Convulsive Mechanisms: Our technology enables the investigation of pro-convulsive compounds such as picrotoxin, shedding light on their effects on network activity and ictal-like discharges in frontal cortex cultures.

Why Choose NeuroProof:

  • Expertise: Our team comprises experts in neuroscience, pharmacology, and assay development, dedicated to advancing epilepsy research and drug discovery.
  • Innovation: We continuously refine our assays and technologies to stay at the forefront of epilepsy research, offering state-of-the-art solutions to our clients.
  • Collaboration: We welcome collaborations with research institutions, pharmaceutical companies, and biotech firms to accelerate the development of novel therapies for epilepsy.

Contact Us:

For further information on our epilepsy assays and how they can drive your research forward.

Contact us for further information!

Cookies user preferences
We use cookies to ensure you to get the best experience on our website. If you decline the use of cookies, this website may not function as expected.
Accept all
Decline all
Read more
Tools used to analyze the data to measure the effectiveness of a website and to understand how it works.
Google Analytics